drugset / Trial / NCT00337155

BAY88-8223, Dose Finding Study in Patients With HRPC

NCT00337155

Phase 2 Completed 122 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.

Timeline

Start
2006-05
Primary completion
2008-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Radium-223 dichloride Other / unclassified 0.025 mbq/kg Other
Subject Radium-223 dichloride Other / unclassified 0.05 mbq/kg Other
Subject Radium-223 dichloride Other / unclassified 0.08 mbq/kg Other